Statistical methods
tumour
TUMOUR
The safety analysis set comprised all patients who received at least one dose of AZD2811. The PK analysis set comprised all patients who received at least one dose of AZD2811 with at least one reportable concentration. The evaluable-for-efficacy analysis set comprised all patients who received at least one dose of AZD2811 and had a baseline tumour assessment. There was no formal statistical analysis of safety and efficacy data. The numbers of patients experiencing each AE were summarised by Medical Dictionary for Regulatory Activities (MedDRA) version 22.1 system organ class, MedDRA preferred term, and CTCAE grade. The ORR and best overall response based on RECIST 1.1 were summarised. AZD2811 blood concentrations and derived PK parameters were summarised by dose regimen. Summary statistics were calculated for area under the curve (AUC), time of maximum concentration (